Small Cap Feast

Small Cap Feast – 20 December 2019

Set Menu AIM:

Total number of AIM Companies (Incl Susp):

Total number of AIM Companies trading: *
* As at

Set Menu NEX Growth:

Total number of NEX Growth Market Companies (Incl Susp): *

Total number of NEX Growth Market Companies trading: *
* As at

Set Menu Standard List:

Total number of Standard List Companies (Incl Susp): *

Total number of Standard List Companies trading: *
* As at

Dish of the Day:

No Joiners Today

Off the Menu:

Murgitroyd has left AIM following a take over by Sovereign Capital Partners

 

Dish of the Day:

Off the Menu:

What’s Cooking in the IPO Kitchen?

NEX Exchange

Greencare Capital  – Investment Vehicle –Hemp, CBD and Medicinal Cannabis . Due 30 Dec. No capital raise.

Main Market (Premium)
The Global Sustainable Farmland Income Trust will invest in a diversified portfolio of operational farmland assets located in major agricultural markets including the United States, Europe, New Zealand, Australia and certain countries within Latin and South America. Raising up to $300m.   Due 28 February

 

Breakfast Buffet

Eagle Eye Solutions (EYE.L) 197p £50.6m

“Eagle Eye, a leading SaaS technology company that creates digital connections enabling personalised, real-time marketing through coupons, loyalty, apps, subscriptions and gift services, is pleased to announce it has signed a new five-year contract for its AIR platform with a top 20 US supermarket (“the Customer”), its first US customer.

The Customer will connect to the Eagle Eye AIR platform hosted in Google Cloud and Eagle Eye will leverage the investment and experience already made in its Canadian operation, as well as establishing a new US client service presence. Eagle Eye’s services will enable the Customer to deliver data-driven, personalised offers and messages to digitally-connected consumers in real time, including offers for Consumer Packaged Goods.”

 

Oxford BioDynamics (OBD.L) 118p £109m

“The biotechnology company focused on the discovery and development of biomarkers, based on regulatory 3D genome architecture, for use within the pharmaceutical and biotechnology industry, is pleased to announce that it has entered into a master service agreement for the development of predictive EpiSwitch™ biomarkers with a top US pharmaceutical company.

This agreement builds on OBD’s proven ability to develop predictive biomarkers for response in immuno-oncology, as presented at The Society for Immunotherapy of Cancer’s (SITC) 34th Annual Meeting in November this year.

Under the terms of the master service agreement, the US pharmaceutical company will be granted access to OBD’s unique EpiSwitch™ technology for use in the development of predictive biomarkers. Details of the agreement and financial terms are not disclosed.”

 

Audioboom Group (BOOM.L) 207.5p £29.06m

 “The leading global podcast company, is pleased to announce the appointment of Stuart Last as Chief Executive Officer and director of the Company, with immediate effect.

Stuart joined Audioboom in 2014 and launched the business in the US, leading all strategy, business development, sales and production operations in the Group’s largest market. He served as Chief Operating Officer before being appointed as the Group’s interim non-Board Chief Executive Officer on 30 September 2019. Before joining Audioboom, he ran podcast operations at Voxnest in New York. Stuart previously held executive positions at the BBC in London, controlling digital strategy for BBC Radio 2, the UK’s largest radio station and overseeing the development of key brands at BBC Radio 1, including the Live Lounge.”

 

Mattioli Woods (MTW.L) 810p £218m

Acquisition of 100% of the issued share capital of The Turris Partnership Limited  from its shareholders  for a total consideration of up to £1.6m. 

Turris specialises in providing chartered financial planning and wealth management advice to its clients, and has over £65m of assets under advice.  Turris was established in 2003 and its experienced team of five staff based in Glasgow will be retained by Mattioli Woods following the acquisition.

Turris generated revenues of £0.45m and profit before taxation of £0.15m for the year ended 30 September 2019.  As at 30 September 2019 Turris’ gross assets were £0.23m and its net assets were £0.20m.  The acquisition is expected to be earnings enhancing in the first full year of ownership.

 

Alexander Mining (AXM.L) 0.04p £1.75m

 Alexander is pleased to announce the proposed acquisition of eLight Group Holdings Ltd which is an Energy Efficiency as a Service company that provides commercial customers with immediate energy and cost reductions with zero upfront investment.  The consideration for the acquisition is £6.6m, to be satisfied by the issue of the Consideration Shares at the Issue Price.

The acquisition, which is subject to shareholder approval, constitutes a reverse takeover under the AIM Rules. 

In the year to 30 June 2019, its first year of trading, eLight secured contracts with a total value of EUR7.4m, earned revenue of EUR4.5m and generated an operating EBITDA loss of EUR0.8m.

 

Beeks Financial Cloud (BKS.L) 104p £53m

 The “cloud computing and connectivity provider for financial markets, is pleased to announce that it has secured two significant contracts, signing a $1m annualised contract with a global financial markets technology provider and a £1.1m contract over three years with a cloud-based payments solution provider. “

 

Immotion (IMMO.L) 6.35p £18.2m

“The UK-based immersive virtual reality (“VR”) ‘Out of Home’ entertainment group, is pleased to provide a trading update. In particular, the Company has grown its installed headset base to 302.”

“Based on our visible pipeline, we expect to see a significant acceleration in new installation activity as we go into the New Year. We believe that our existing estate, combined with expected headset installations, will result in an installed base that should deliver monthly underlying EBITDA breakeven (based on our forecasted operating costs) by or around the end of Q1 2020. “

“We expect 2019 full year underlying EBITDA loss to be in line with expectations and revenue to be in the range of £3.6-£3.8m, (towards the lower end of expectations). “

 

Warpaint London (W7L.L) 69.5p £53.3m

The specialist supplier of colour cosmetics and owner of the W7 and Technic brands currently anticipates that Group sales for the financial year to 31 December 2019 will be approximately £50m, in line with current guidance.

As the Company has previously outlined, a number of factors, including the geographic mix of sales, adverse exchange rate movements and the Group’s investment in its strategy for future growth, particularly in the US, are having an impact on profitability this  financial year. Consequently, the Company’s board currently expects adjusted PBT for the year ending 31 December 2019 (excluding amortisation in connection with acquisitions, share incentive scheme costs and exceptional items, which the board expects to total approximately £2.8m) will now be in the range of £5.1m to £5.5m.

 

Head Chef:

Derren Nathan
0203 764 2344
derren.nathan@hybridan.com

*A corporate client of Hybridan LLP

Disclaimer

This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.

The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.

The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).

Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.

This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.

In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.

Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.

Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.

Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.

This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.

MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.

Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.

If you would like to unsubscribe, please email enquiries@hybridan.com with “unsubscribe me”.